Published in Cancer Immunology Research · View the paper (DOI)
A simple blood test identifying patients unlikely to benefit from immunotherapy for bladder cancer could save months of unnecessary treatment. The test measures pro-inflammatory molecule Interleukin-2 release from immune cells before therapy and correctly predicted therapy outcome in almost 80% of cases.
Coverage from 3 institutions